ClinicalTrials.gg
Not yet recruitingNCT06750341Updated Dec 27, 2024

Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol

A Phase 2 interventional study of QLC7401 and Placebo in Primary Hypercholesterolemia or Mixed Hyperlipidemia, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the efficacy, safety, pharmacodynamics and immunogenicity of QLC7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized lipid-lowering therapy.

02

Conditions studied

  • Primary Hypercholesterolemia or Mixed Hyperlipidemia
03

In context

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

This study's planned enrollment of 156 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.

Browse Hyperlipoproteinemia Type II studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged ≥18 years of age.
  • Serum LDL-C ≥1.8mmol/L for ASCVD participants or ≥2.6mmol/L for other participants at screening.
  • Fasting TG \<400mg/dL (\<4.5mmol/L) at screening.
  • Stable lipid-lowering therapy for ≥4 weeks at randomization.
  • Understand the study procedures and methods, volunteer to participate in the study, and sign the .

Exclusion criteria

Exclusion Criteria:

  • Having the following diseases or treatment history: (1) cardiac function as defined by the (NYHA) grade II-IV at screening or randomization or latest detected \<30%; (2) CVD events within 3 months; (3) uncontrolled severe hypertension; (4) previous diagnosis of familial hypercholesterolemia; (5) have known allergic reaction to experimental drug, or have severe allergic reaction to other drugs; (6) inadequate organ functions or history; (7) prior exposure to other RNA inhibitors within 2 years.
  • Any of the laboratory indicators met the following criteria at screening or at randomization: (1) or AST exceeding 2 times the (ULN), or total exceeding 1.5 times ULN; (2) creatine kinase (CK) exceeding 3 times ULN; (3) TSH is less than the lower limit or normal (LLN) or exceeds 1.5 times ULN.
  • General conditions: (1) male or female participants who do not agree to use high-efficiency during the trial and for 6 months after the last dosing; (2) women who are pregnant or lactating.
  • The investigator determines that the participants have poor compliance or have any factors that may prevent them from participating in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    QLC7401 100mg

    QLC7401 100 mg subcutaneous injection

    Drug: QLC7401

  • Experimental
    QLC7401 300mg

    QLC7401 300 mg subcutaneous injection

    Drug: QLC7401

  • Experimental
    QLC7401 500mg

    QLC7401 500 mg subcutaneous injection

    Drug: QLC7401

  • Placebo comparator
    Placebo

    Placebo 100/300/500 mg subcutaneous injection

    Drug: Placebo

Interventions

  • QLC7401 combined with lipid-lowering agents

  • DrugPlacebo

    Placebo combined with lipid-lowering agents

06

What researchers measure

Primary outcomes

  1. Percentage changes in LDL-C from baseline to Day 180 and Day 270

    Time frame: 80 days and 270 days

Secondary outcomes

  1. Percentage changes in LDL-C from baseline at each subsequent visit to Day 360

    Time frame: 360 days

  2. Value changes in LDL-C from baseline at each subsequent visit to Day 360

    Time frame: 360 days

  3. Percentage changes in PCSK9 from baseline at each subsequent visit to Day 360

    Time frame: 360 days

  4. Value changes in PCSK9 from baseline at each subsequent visit to Day 360

    Time frame: 360 days

  5. Percentage changes in non-HDL-C, Apo B, TC/HDL-C, Apo A1, Apo B/Apo A1, Lp (a), and TG from baseline to Day 180, Day 270, and Day 360

    Time frame: 360 days

  6. Value changes in non-HDL-C, Apo B, TC/HDL-C, Apo A1, Apo B/Apo A1, Lp (a), and TG from baseline to Day 180, Day 270, and Day 360

    Time frame: 360 days

  7. Proportion of participants with LDL-C greater than 80% of baseline value at Day 180, Day 210, Day 270, and Day 360

    Time frame: 360 days

  8. Duration of treatment for participants to return to 80% of baseline value or greater LDL-C or PCSK9 protein

    Time frame: 360 days

  9. Proportion of participants who attained global lipid modification targets for level of ASCVD risk

    Time frame: 360 days

  10. Number of participants with adverse events and injection site reactions, with abnormal vital signs, abnormal physical examination, abnormal 12-ECG, abnormal laboratory assessments

    Time frame: 360 days

  11. ADA incidence

    Time frame: 360 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2025; primary completion for Jun 2026, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 27, 2024
StartEst.
Feb 2025
Primary completionEst.
Jun 2026
CompletionEst.
Sep 2026
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06750341
Responsible party
Sponsor
First posted
Dec 27, 2024
Start date
Feb 2025 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Dec 27, 2024

Study contacts

Ming Zhao
Contact
ming.zhao@qilu-pharma.com
086+15666662408

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLC7401

Start the discussion